J Korean Med Assoc.  2016 Jan;59(1):8-13. 10.5124/jkma.2016.59.1.8.

Thromboembolism in pregnancy

• Park JC

• KMID: 2195162
• DOI: http://doi.org/10.5124/jkma.2016.59.1.8

Abstract

Pregnancy-related venous thromboembolism (VTE) is one of the leading causes of maternal morbidity and mortality, developed in the antenatal and postpartum periods of pregnancy. The incidence of VTE during normal pregnancy is four- to six-fold higher than in the general reproductive aged female population. Physiologic changes such as hypercoagulable state, decreased venous capacitance, and reduced venous blood flow due to mechanical obstruction from gravid uterus compromise this condition. The prominent risk factors for VTE are thrombophilia, history of circulatory disease and previous VTE, preeclampsia and related disorders, and Cesarean section. In case of suspicion of VTE, prompt diagnosis and management are needed with the caution of potential adverse effects on the fetus. Low molecular weight heparin treatment is preferred due to better safety, more consistent bioavailability, ease of administration, lower risk of drug-related osteoporosis and thrombocytopenia and easier monitoring. For pregnant women with acute VTE, adjusted-dose subcutaneous low molecular weight heparin should be administrated antenatally and continued for at least 6 weeks postpartum. For prevention of VTE, mechanical prophylaxis such as physiotherapy, exercise, compression stockings, and intermittent pneumatic compression devices could be used. Thromboprophylaxis should also be considered for pregnant subjects with certain risks such as carriers of molecular thrombophilia or previously experienced VTE.

Keyword

Pregnancy; Thromboembolism; Low-molecular-weight heparin; Thromboprophylaxis

MeSH Terms

Biological Availability
Cesarean Section
Diagnosis
Female
Fetus
Heparin, Low-Molecular-Weight
Humans
Incidence
Intermittent Pneumatic Compression Devices
Mortality
Osteoporosis
Postpartum Period
Pre-Eclampsia
Pregnancy*
Pregnant Women
Risk Factors
Stockings, Compression
Thrombocytopenia
Thromboembolism*
Thrombophilia
Uterus
Venous Thromboembolism
Heparin, Low-Molecular-Weight

Reference

1. Kourlaba G, Relakis J, Kontodimas S, Holm MV, Maniadakis N. A systematic review and meta-analysis of the epidemiology and burden of venous thromboembolism among pregnant women. Int J Gynaecol Obstet. 2015; Oct. 9. [Epub]. DOI: 10.1016/j.ijgo.2015.06.054.

2. Bagaria SJ, Bagaria VB. Strategies for diagnosis and prevention of venous thromboembolism during pregnancy. J Pregnancy. 2011; 2011:206858.

3. James AH. Thrombosis in pregnancy and maternal outcomes. Birth Defects Res C Embryo Today. 2015; 105:159–166.

4. Konkle BA. Diagnosis and management of thrombosis in pregnancy. Birth Defects Res C Embryo Today. 2015; 105:185–189.

5. Parunov LA, Soshitova NP, Ovanesov MV, Panteleev MA, Serebriyskiy II. Epidemiology of venous thromboembolism (VTE) associated with pregnancy. Birth Defects Res C Embryo Today. 2015; 105:167–184.

6. D'Uva M, Di Micco P, Strina I, De Placido G. Venous throm-boembolism and pregnancy. J Blood Med. 2010; 1:9–12.

7. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. American College of Chest Physicians. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141:2 Suppl. e691S–e736S.

8. Arya R. How I manage venous thromboembolism in preg-nancy. Br J Haematol. 2011; 153:698–708.

9. Burgazli KM, Bilgin M, Kavukcu E, Altay MM, Ozkan HT, Coskun U, Akdere H, Ertan AK. Diagnosis and treatment of deep-vein thrombosis and approach to venous thromboem-bolism in obstetrics and gynecology. J Turk Ger Gynecol Assoc. 2011; 12:168–175.

10. Che Yaakob CA, Dzarr AA, Ismail AA, Zuky Nik Lah NA, Ho JJ. Anticoagulant therapy for deep vein thrombosis (DVT) in pregnancy. Cochrane Database Syst Rev. 2010; (6):CD007801.

11. Royle G, Barry CL, Blacklock H, Lake Y. D-D dimers: a poor correlate of PPIH and subsequent outcomes. Int J Gynaecol Obstet. 1998; 62:37–42.

12. Nishii A, Noda Y, Nemoto R, Ushiro K, Ohno T, Mochizuki Y, Yoshihara H, Taguchi A, Uchino N, Ohkawara S. Evaluation of D-dimer during pregnancy. J Obstet Gynaecol Res. 2009; 35:689–693.

13. Leung AN, Bull TM, Jaeschke R, Lockwood CJ, Boiselle PM, Hurwitz LM, James AH, McCullough LB, Menda Y, Paidas MJ, Royal HD, Tapson VF, Winer-Muram HT, Chervenak FA, Cody DD, McNitt-Gray MF, Stave CD, Tuttle BD. ATS/STR Committee on Pulmonary Embolism in Pregnancy. An official American Thoracic Society/Society of Thoracic Radiology clinical practice guideline: evaluation of suspected pulmonary embolism in pregnancy. Am J Respir Crit Care Med. 2011; 184:1200–1208.

14. Quiroz R, Kucher N, Zou KH, Kipfmueller F, Costello P, Goldhaber SZ, Schoepf UJ. Clinical validity of a negative com-puted tomography scan in patients with suspected pulmonary embolism: a systematic review. JAMA. 2005; 293:2012–2017.

15. Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Preg-nancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008; 6:632–637.

16. Henriksson P, Westerlund E, Wallen H, Brandt L, Hovatta O, Ekbom A. Incidence of pulmonary and venous thromboem-bolism in pregnancies after in vitro fertilisation: cross sectional study. BMJ. 2013; 346:e8632.

17. Lim W, Eikelboom JW, Ginsberg JS. Inherited thrombophilia and pregnancy associated venous thromboembolism. BMJ. 2007; 334:1318–1321.

18. Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, Walker ID, Greaves M, Brenkel I, Regan L, Greer IA. Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2006; 132:171–196.

19. Ziakas PD, Poulou LS, Pavlou M, Zintzaras E. Thrombophilia and venous thromboembolism in pregnancy: a meta-analysis of genetic risk. Eur J Obstet Gynecol Reprod Biol. 2015; 191:106–111.

20. Battinelli EM, Marshall A, Connors JM. The role of thrombo-philia in pregnancy. Thrombosis. 2013; 2013:516420.

21. Stegnar M. Thrombophilia screening: at the right time, for the right patient, with a good reason. Clin Chem Lab Med. 2010; 48:Suppl 1. S105–S113.

22. Brill-Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, Geerts W, Kovacs M, Weitz JI, Robinson KS, Whit-tom R, Couture G. Recurrence of Clot in This Pregnancy Study Group. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med. 2000; 343:1439–1444.

23. Won HS, Kim do Y, Yang MS, Lee SJ, Shin HH, Park JB. Pregnancy-induced hypertension, but not gestational diabetes mellitus, is a risk factor for venous thromboembolism in pregnancy. Korean Circ J. 2011; 41:23–27.

24. Romualdi E, Dentali F, Squizzato A, Ageno W. Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature: a reply to a rebuttal. J Thromb Haemost. 2013; 11:788–789.

25. Rodie VA, Thomson AJ, Stewart FM, Quinn AJ, Walker ID, Greer IA. Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series. BJOG. 2002; 109:1020–1024.

26. De Sancho MT, Khalid S, Christos PJ. Outcomes in women receiving low-molecular-weight heparin during pregnancy. Blood Coagul Fibrinolysis. 2012; 23:751–755.

27. Pabinger I, Grafenhofer H, Kaider A, Kyrle PA, Quehenberger P, Mannhalter C, Lechner K. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost. 2005; 3:949–954.

28. Di Micco P, D'Uva M. The role of low molecular weight heparin to prevent miscarriage in thrombophilic women. Thromb Haemost. 2005; 94:897–898.